PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of biotechhealthLink to Publisher's site
 
Biotechnol Healthc. 2007 December; 4(6): 61.
PMCID: PMC2651730

Additional Indications Drive Higher Specialty Spending

A handful of classes makes up more than three fourths of prescriptions filled through specialty pharmacies. Additional indications for existing medications within these classes — primarily therapies for inflammatory conditions and oncology — play a large part in increased utilization.

According to Express Scripts’ Drug Trend Report, released earlier this year, new indications were largely responsible for a nearly 18 percent increase in utilization of biologic therapies marketed for treatment of inflammatory conditions. In 2006, for instance, use of etanercept (Enbrel) and adalimumab (Humira) — previously approved for rheumatoid arthritis — increased, a year after the U.S. Food and Drug Administration granted the products indications for psoriatic arthritis.

This phenomenon may continue. Eculizumab (Soliris), approved last March for the treatment of a rare blood disorder, is considered a potential RA therapy, and several new products in the pipeline undergoing study for RA may eventually prove useful for other inflammatory conditions.

An external file that holds a picture, illustration, etc.
Object name is f1-bth04_6p061.jpg
An external file that holds a picture, illustration, etc.
Object name is f2-bth04_6p061.jpg

Articles from Biotechnology Healthcare are provided here courtesy of MediMedia, USA